← Back to Search

Incentive-Based Interventions for Smoking Cessation

N/A
Waitlist Available
Led By Maya Vijayaraghavan, MD, MAS
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are 18 years or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether providing incentives for smoking cessation (like cash) to people experiencing homelessness makes them more likely to quit smoking.

Who is the study for?
This trial is for homeless adults who smoke daily, have smoked over 100 cigarettes in their lifetime, and want to quit within six months. They must be getting or willing to start smoking cessation counseling at the Tom Waddell Urban Health Center, be over 18 years old, meet homelessness criteria, and speak English. Pregnant individuals or those with a recent heart attack can't participate.
What is being tested?
The study tests a contingency management approach that rewards quitting smoking with cash incentives among the homeless. It aims to see if this method is practical and well-received when offered through safety net clinics.
What are the potential side effects?
Since this intervention involves behavioral changes rather than medication, there are no direct side effects like you'd expect from drugs. However, participants may experience typical nicotine withdrawal symptoms such as irritability, cravings, or difficulty concentrating.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Median number of carbon monoxide (CO) negative samples
Median total number of counseling sessions attended
Proportion of the sample retained as a result of retention procedures over time
Secondary study objectives
Proportion of participants who achieve point prevalence abstinence
Proportion of participants who achieve prolonged abstinence over time

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Control GroupExperimental Treatment1 Intervention
Participants who choose to attend smoking cessation in the usual care setting at TWUHC will receive a basic $5 payment for attending each study visit.
Group II: Contingency Management (CM)Experimental Treatment1 Intervention
In addition to receiving usual cessation care at the Tom Waddell Urban Health Center (TWUHC), CM intervention participants with CO-verified abstinence will obtain a CM incentive payment, via gift cards and/or cash redeemable in national retail chains.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency Management - Increasing
2021
N/A
~90
Fixed payments
2021
N/A
~90

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,867 Total Patients Enrolled
Tobacco Related Disease Research ProgramOTHER
26 Previous Clinical Trials
26,262 Total Patients Enrolled
Maya Vijayaraghavan, MD, MASPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
400 Total Patients Enrolled

Media Library

Contingency Management Clinical Trial Eligibility Overview. Trial Name: NCT04982952 — N/A
Tobacco Smoking Research Study Groups: Control Group, Contingency Management (CM)
Tobacco Smoking Clinical Trial 2023: Contingency Management Highlights & Side Effects. Trial Name: NCT04982952 — N/A
Contingency Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT04982952 — N/A
~20 spots leftby Dec 2025